HOOK3 and non-small cell lung carcinoma: Sun et al. [12] demonstrated that midazolam reduced cisplatin resistance in cisplatin-resistant NSCLC cells by regulating the miR-194-5p/HOOK3 axis, implying that midazolam could be used as an adjuvant drug for NSCLC treatment in clinical practices.